Abrégé

LachnospiraceaeLachnospiraceaeLachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.

Classes IPC  ?

• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
• C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries

Abrégé

A disposable imaging phantom including a top housing having an inlet, and outlet, and first chamber in communication with the inlet and outlet and a bottom housing having a second chamber. The bottom housing connects to the top housing. The first and second chamber are configured to receive a first fluid. The first chamber is configured to receive a second fluid through the inlet to displace the first fluid through the outlet. The imaging phantom also includes a membrane assembly configured to be positioned between portions of the top and bottom housings. The membrane assembly includes a semi-permeable membrane configured to permit diffusion of the second fluid from the first chamber into the second chamber.

Classes IPC  ?

• G01R 33/58 - Etalonnage des systèmes d'imagerie, p.ex. utilisant des sondes d'essai
• G01R 33/563 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p.ex. angiographie à écoulement contrasté

Abrégé

The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.

Classes IPC  ?

• A61K 38/06 - Tripeptides
• A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
• A61K 47/22 - Composés hétérocycliques, p.ex. acide ascorbique, tocophérol ou pyrrolidones
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The current disclosure provides methods for the production of 'vaccine-like' antiviral preparations. The present disclosure provides compounds for the treatment of a wide range of enveloped viral diseases and conditions. The present disclosure further provides methods for treating, preventing, and/or suppressing an enveloped virus disease in a subject using the compounds disclosed herein as well as pharmaceutical compositions comprising such compound.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
• A61K 39/145 - Orthomyxoviridae, p.ex. virus de l'influenza
• A61K 39/215 - Coronaviridae, p.ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/11 - Orthomyxoviridae, p.ex. virus de l'influenza
• C07K 14/165 - Coronaviridae, p.ex. virus de la bronchite infectieuse aviaire

Abrégé

Provided herein are compositions and methods for detecting bacteria associated with bacterial vaginosis.

Classes IPC  ?

• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, epilepsy, autism spectrum disorders, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• C07D 265/36 - Oxazines-1, 4; Oxazines-1, 4 hydrogénées condensés avec des carbocycles condensés avec un cycle à six chaînons
• C07D 279/16 - Thiazines-1, 4; Thiazines-1, 4 hydrogénées condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle à six chaînons
• A61K 31/538 - 1,4-Oxazines, p.ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
• A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p.ex. chorée, dyskinésie
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

Clinical detection or diagnosis of transplant rejection currently utilizes various methods that rely on qualitative rather than quantitative data, or quantitative data that has low sensitivity and/or has a high rate of operator error. Provided herein are methods for identifying kidney transplant rejection in patents that is automated and consistent for the user. Further described herein are cut-offs for transplant biomarkers that relate to renal transplantation stability or rejection.

Classes IPC  ?

• G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
• C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux

Abrégé

Wearable devices for measuring health indicators such as bilirubin are provided. The device includes a skin-facing side including a circuit board. The circuit board includes a spectrometer integrated circuit, at least one light emitting diode (LED) configured to direct light at the subject's skin where the LED is operably connected to a power source, at least one photodetector configured to receive light reflected from the subject's skin, and a microcontroller configured to perform spectral subtraction of said reflected light.

Classes IPC  ?

• G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale
• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang

Abrégé

Provided herein are methods for treating or preventing inflammatory skin disorders, such as Hidradenitis suppurativa, by administering to a subject having or at risk of developing the inflammatory skin disorder an agent that inhibits NK cell activity.

Classes IPC  ?

• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
• A61K 47/51 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification

Abrégé

The present disclosure provides for compounds including modified saponin compounds, pharmaceutical compositions including modified saponin compounds, methods of use of the modified saponin compounds and the pharmaceutical compositions, methods of making modified saponin compounds, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating viral infection and other diseases.

Classes IPC  ?

• C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques

Abrégé

The present disclosure relates to techniques for anti-myopia visual display therapy using a simulated myopic blur. In one particular aspect, a method is provided that includes obtaining a pattern for a digital image, selecting a color channel of the digital image, applying a blur effect to the color channel that modifies the digital image to have a simulated blur, and providing anti-myopia visual display therapy to a subject using the modified digital image. The therapy comprises: (i) rendering the modified digital image on a display of a computing device within a visual environment of the subject, or (ii) placing the modified digital image within the visual environment of the subject, based on an optimal viewing time.

Classes IPC  ?

• H04N 13/15 - Aspects des signaux d’images en rapport avec la couleur
• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• G06F 18/40 - Dispositions logicielles spécialement adaptées à la reconnaissance des formes, p.ex. interfaces utilisateur ou boîtes à outils à cet effet
• H04N 13/128 - Ajustement de la profondeur ou de la disparité
• A61F 9/00 - Procédés ou dispositifs pour le traitement des yeux; Dispositifs pour mettre en place des verres de contact; Dispositifs pour corriger le strabisme; Appareils pour guider les aveugles; Dispositifs protecteurs pour les yeux, portés sur le corps ou dans la main

Abrégé

egg., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• A61K 31/505 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime
• A61K 31/33 - Composés hétérocycliques
• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
• A61K 31/405 - Acides indole-alkanecarboxyliques; Leurs dérivés, p.ex. tryptophane, indométhacine

Abrégé

CD206 targeted peptide conjugates are provided. Aspects of the conjugates include a CD206 binding peptide conjugated to a label or therapeutic agent. Also provided are methods of using the conjugates, e.g., in diagnostic or therapeutic applications.

Classes IPC  ?

• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 51/08 - Peptides, p.ex. protéines
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
• G06T 7/00 - Analyse d'image
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

22. Also described are NO storage cartridges for use in the systems.

Classes IPC  ?

• B01D 53/56 - Oxydes d'azote
• A61M 16/12 - Préparation de gaz ou vapeurs à respirer par mélange de gaz différents

Abrégé

Epileptic seizures cannot be effectively controlled in many patients, thereby necessitating the development of novel therapeutic agents. Activation of the A1 receptor (A1R) by endogenous adenosine is an intrinsic mechanism to self-terminate seizures and protect neurons from excitotoxicity. However, targeting A1R for neurological disorders has been hindered by side effects associated with its broad expression outside the nervous system. Herein, the neural-specific A1R/neurabin/RGS4 complex that dictates A1R signaling strength and response outcome in the brain is targeted. A peptide was developed to block the A1R-neurabin interaction and enhance A1R activity. Anticonvulsant and neuroprotective effects are achieved through enhanced A1R function in response to endogenous adenosine in the brain, thus avoiding side effects associated with A1R activation in peripheral tissues and organs.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
• C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

A method of optimizing vehicle mobility performance includes receiving technical parameters for each wheel associated with wheel power of the particular wheel on a particular terrain. The method includes determining an optimal vehicle mobility performance by determining an optimal tire slippage for one wheel based on the set of technical parameters for the wheel and individually determining an optimal tire slippage for another wheel based on the set of technical parameters for the other wheel. A system may utilize such a method to control mobility performance in a vehicle such as, but not limited to, an autonomous ground vehicle.

Classes IPC  ?

• B60W 40/12 - Calcul ou estimation des paramètres de fonctionnement pour les systèmes d'aide à la conduite de véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier liés à des paramètres du véhicule lui-même
• B60W 60/00 - Systèmes d’aide à la conduite spécialement adaptés aux véhicules routiers autonomes
• B60W 40/02 - Calcul ou estimation des paramètres de fonctionnement pour les systèmes d'aide à la conduite de véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier liés aux conditions ambiantes
• B60W 50/00 - COMMANDE CONJUGUÉE DE PLUSIEURS SOUS-ENSEMBLES D'UN VÉHICULE, DE FONCTION OU DE TYPE DIFFÉRENTS; SYSTÈMES DE COMMANDE SPÉCIALEMENT ADAPTÉS AUX VÉHICULES HYBRIDES; SYSTÈMES D'AIDE À LA CONDUITE DE VÉHICULES ROUTIERS, NON LIÉS À LA COMMANDE D'UN SOUS-ENSEMBLE PARTICULIER - Détails des systèmes d'aide à la conduite des véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier

Abrégé

Disclosures herein are directed to methods of regenerating cardiomyocytes in heart tissue damaged as a result heart failure in a subject by administering one or more aminoglycosides to a subject in need thereof. Accordingly, disclosures herein are also toward methods of administering one or more aminoglycosides to treat heart failure in a subject in need thereof.

Classes IPC  ?

• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• C07D 473/32 - Atome d'azote
• A61K 31/52 - Purines, p.ex. adénine
• A61P 39/02 - Antidotes

Abrégé

Various examples are provided related to blood-interface materials for metallic biomedical implants and devices. In one example, a bio-compatible implant or device includes an organosilane plasma polymerization (OPP) coating disposed on a surface of a metallic structure. The OPP coating can include inorganic silica disposed on bare metal of the metallic structure and forming a nano-textured surface. In another example, a biocompatible implant or device includes a composite coating disposed on a surface of the metallic structure. The composite coating can include silica-DEA, silica-MEA or silica-TEA coating disposed on bare metal of the metallic structure and forming a nano-textured surface. In another example, a method includes providing a metallic structure and exposing it to an OPP process to form a coating on the surface of the metallic structure to form the bio-compatible implant or device.

Classes IPC  ?

• A61L 29/08 - Matériaux de revêtement
• A61L 27/14 - Matériaux macromoléculaires
• A61L 29/12 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent

Abrégé

For many proteins, aggregation starts from phase separation, which frequently results from intermolecular interactions mediated by disordered protein regions. These disordered regions often contain repetitive sequences (also known as low-complex regions). In some embodiments, the protein solubilizing method described herein is applicable for proteins with the following two classes of repetitive sequences. Disclosed herein are mimic peptide sequences > 3 amino acids that can increase protein solubility of proteins having disordered protein regions.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• C07C 323/60 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des groupes carboxyle liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné avec l'atome de carbone d'au moins un des groupes carboxyle lié à des atomes d'azote
• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides

Abrégé

The present disclosure describes system and methods for determining cardiac events from a physiological data signal and optionally constructing a Pressure-Volume (PV) loop display from non-simultaneously acquired measurements of pressure and volume data. One such method comprises obtaining, by a computing device, a physiological data signal of a heart of an individual; identifying, by the computing device, features of the physiological data signal and applying the features as inputs to a prediction model; determining, by the computing device using the prediction model, the cardiac events for one or more valves of the heart, wherein the cardiac events include timing of opening and closing of the one or more valves of the heart; and outputting, by the computing device, the cardiac events determined using the prediction model. The physiological data signal can be combined with non-simultaneously acquired volume data to create a PV loop display.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus

Abrégé

A method of treating a central nervous system cancer in a subject comprising administering to the subject a preconditioning agent, and, administering to the subject a therapeutic dose of an oncolytic virus; wherein the preconditioning agent is an immunostimulant selected from the group consisting of a toll-like receptor agonist, a subtherapeutic dose of an oncolytic virus, and/or an interferon that induces a transient anti-viral response and/or upregulates an interferon response; and wherein the preconditioning agent and the therapeutic dose of the oncolytic virus is administered to the subject's cerebrospinal fluid or periependymal region. Provided herein are methods of treating a central nervous system cancer in a subject. This method allows for intrathecal administration of oncolytic virus, which, until the present invention, resulted in unacceptable toxicity.

Classes IPC  ?

• A61K 35/76 - Virus; Particules sous-virales; Bactériophages
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 35/00 - Agents anticancéreux
• A61K 35/768 - Virus oncolytiques non prévus dans les groupes
• A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
• C12N 15/869 - Vecteurs herpèsviraux

Abrégé

Disclosed is a method for reducing metastasis and/or tumor growth in a subject with cancer by administering an effective amount of an inhibin antibody to the subject with cancer. In particular, the subject may have ovarian cancer and the administration of inhibin antibody may impair tumor growth.

Classes IPC  ?

• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire

Abrégé

Methods for using BMP9 or an agonist thereof to reduce metastasis of cancer are disclosed. The method may include administering an effective amount of BMP9 or an agonist thereof to a subject in need thereof, to reduce metastasis of cancer. The subject may be a human.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissance; Régulateurs de croissance
• C07K 14/51 - Facteur morphogénique osseux; Ostéogénine; Facteur ostéogénique; Facteur inducteur d'os
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

Provided herein are compositions and methods for preparing a purified population of single chain Mycobacterium smegmatis porins.

Classes IPC  ?

• C12P 21/00 - Préparation de peptides ou de protéines
• B01D 15/08 - Adsorption sélective, p.ex. chromatographie
• C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
• C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
• C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger

Abrégé

The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.

Classes IPC  ?

• A61K 39/42 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire viraux
• C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
• C12N 5/0781 - Cellules B; Leurs progéniteurs
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus

Abrégé

Provided is a modular offloading walker that offloads strain from a lower limb or foot. The walker includes a modular upper component and a modular lower component. The upper component can include a modular anterior component and a modular posterior component. The lower component includes a foot plate having a rocker sole and upright stays coupled to medial and lateral edges of the foot plate. The upright stays can have an adjustable height and the upper component can be removably attached to the upright stays.

Classes IPC  ?

• A43B 7/20 - Supports de jointures, p.ex. supports de cou-de-pied Éléments pour supporter ou tenir la cheville
• A43B 7/14 - Chaussures avec dispositions médicales ou hygiéniques avec éléments pour soutenir le pied
• A43B 7/16 - Chaussures avec dispositions médicales ou hygiéniques avec éléments pour soutenir le pied à talonnettes intérieures
• A43B 23/22 - Supports pour la cambrure de la tige

Abrégé

Lactobacillus sppLactobacillus sppLactobacillus spp. strains, the compositions can include herbal extracts from holy basil, turmeric, and vasaka for respiratory relief.

Classes IPC  ?

• A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

An AI system and method are provided that enable more accurate and efficient medical impressions to be automatically generated from reports of medical findings. The AI system and method automatically generate a summary, or impression, of a medical report from digitized text-based findings entered by a clinician. A user who may or may not be the person who generated the report of medical findings designates a medical professional who will be finalizing the report. The AI system selects the AI model that is associated with the medical professional who has been designated and uses the AI model to generate the impression section of the report.

Classes IPC  ?

• G06F 7/00 - Procédés ou dispositions pour le traitement de données en agissant sur l'ordre ou le contenu des données maniées
• G06F 17/00 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des fonctions spécifiques
• G10L 15/00 - Reconnaissance de la parole

Abrégé

A surgical tool support system is provided. The system includes a support portion, a swivel arm, and a tool holder for holding a surgical tool coupled to a distal end of the swivel arm. The tool holder can have a locking joint controlled by an actuator such that the tool holder can be locked into a position along multiple axes of rotation. The system can offset the force required by a user to move the surgical tool, thereby reducing fatigue.

Classes IPC  ?

• A61B 90/50 - Supports pour instruments chirurgicaux, p.ex. bras articulés
• A61B 90/57 - Attaches accessoires

Abrégé

The present disclosure is concerned with biaryl aminomaleimide compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases ( e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• C07D 207/02 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle 
• C07D 207/18 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle  comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
• C07D 207/444 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle  comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant deux atomes d'oxygène liés directement en positions 2 et 5 par une double liaison

Abrégé

e.ge.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• A61K 31/47 - Quinoléines; Isoquinoléines
• A61K 31/472 - Isoquinoléines non condensées, p.ex. papavérine
• C07D 215/02 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle

Abrégé

The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

Provided herein are NO generating systems, methods for generating NO for inhaled therapy, and methods of treating patients in need of inhaled NO. The systems can include a reaction vessel having a headspace for NO accumulation, a NO storage system, and a gas mixing chamber. NO gas generated in the reaction vessel can be delivered to the NO storage system via pressure generated by generation of the NO gas, then the NO gas is mixed with a carrier gas in a gas mixing chamber. NO can be generated at the point of patient delivery.

Classes IPC  ?

• A61M 16/12 - Préparation de gaz ou vapeurs à respirer par mélange de gaz différents
• A61M 16/20 - Valves spécialement adaptées aux dispositifs respiratoires médicaux
• A61M 16/10 - Préparation de gaz ou vapeurs à respirer
• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p.ex. bouche-à-bouche; Tubes trachéaux
• A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

The present disclosure relates to a method of detecting airflow obstruction using one or more novel metrics associated with a spirometry reading for a subject. The method includes obtaining spirometry data from a subject, generating a first measurement curve and a second measurement curve based on the obtained data for the subject, performing at least a first curve-fitting on the first measurement curve using a Least Absolute Residuals algorithm to estimate a function which closely approximates the spirometry data for the subject by minimizing a sum of absolute deviation, determining a first metric that describes a rate of volume increase based on the estimated function, comparing the first metric to one or more threshold values, and determining a presence or absence of airflow obstruction for the subject based on the comparison of the first metric to the one or more threshold values.

Classes IPC  ?

• A61B 5/087 - Mesure du débit respiratoire

Abrégé

The present disclosure provides for pharmaceutical composition and methods of treating a condition using the pharmaceutical composition. The condition to be treated in a subject in need of treatment can include an infection or non-viral hyper-inflammation/immune hyperactivation condition. The infection can be a coronavirus infection, HIV infection, influenza infection, or the like, where a direct or indirect result of the infection can be respiratory distress, oxidative stress, and the like that can lead to acute respiratory distress syndrome (ARDS) and/or organ dysfunction or failure.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
• C07J 15/00 - Stéroïdes stéréochimiquement purs, contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, ayant un squelette partiellement ou totalement inversé, p.ex. rétro-stéroïdes, L-isomères
• A61P 31/12 - Antiviraux

Abrégé

A coil wire and method of using the coil wire to navigate blood vessels are provided. The coil wire is configured to facilitate coaxial catheter advancement over at least a part of the length of the coil wire. Existing guidewires utilize the distal tip of a guidewire to select the vessel origins by shaping it (either during fabrication or by the operating physician) in such a way that the tip will point into the desired vessel as the wire is advanced. The coil wire of the present disclosure functions in a unique manner: its distal tip resumes a pre-formed three-dimensional coil configuration as it is expressed from the catheter. This shape catches the flow of moving blood and propels the coil wire forward while unfurling the coil. As the coil wire is advanced, the small outer diameter of the unfurled coil allows it to pass deep into the selected vessel.

Classes IPC  ?

• A61B 17/12 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets pour ligaturer ou comprimer par un autre moyen les parties tubulaires du corps, p.ex. les vaisseaux sanguins ou le cordon ombilical
• A61M 25/00 - Cathéters; Sondes creuses
• A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
• A61M 25/085 - Propulsion au moyen de fluides

Abrégé

This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/5025 - Pyridazines; Pyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to treatments for coronavirus infections by administering a neutrophil elastase inhibitor, such as alvelestat.

Classes IPC  ?

• A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 7/02 - Agents antithrombotiques; Anticoagulants; Anti-agrégants plaquettaires
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Relationships between morphological changes to an eye due to intraocular pressure changes and blood perfusion and nerve function changes in the retina are determined by colocalizing retinal perfusion data, optic nerve head (ONH) mechanical deformation data, visual field data and nerve fiber data. Perfusion and nerve function changes from intraocular pressure (IOP) changes are determined by colocalizing retinal perfusion data with ONH mechanical deformation data, visual field data and nerve fiber data. Optical coherence tomography-angiography (OCT-A) can be used to generate retinal perfusion data, mechanical deformation data for an imaged volume, and nerve fiber data. A three-dimensional model (e.g., connectivity map or connectivity model) of the vasculature and nerve fibers can be generated from the OCT-A imaging data and used to predict changes in blood perfusion and nerve function in various areas of the retina due to IOP-induced mechanical deformations.

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c. à d. recalage des images utilisant des procédés basés sur les caractéristiques

Abrégé

Peptides are provided for the treatment of various diseases and conditions, including infection, sepsis, and trauma as well as immunosuppression resulting from infection, sepsis and/or trauma. Methods of treating an infection, neutrophil dysfunction, sepsis, trauma, immunosuppression associated with infection, sepsis and/or trauma, organ injury associated with any of the foregoing (such as, but not limited to, ARDS, lung fibrosis, IPF, and COPD), or a symptom of any of the foregoing comprising administering a disclosed peptide are also provided as well as pharmaceutical compositions and kits comprising a disclosed peptide.

Classes IPC  ?

• A61K 31/727 - Héparine; Héparane
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes

Abrégé

A urine collection device is provided. The urine collection device includes a basin configured to fit a perineal region of a female human subject and to receive urine; a lip attached to the basin and having a contact surface for attachment to the perineal region; a ridge extending into the basin and disposed along an inferior portion of the lip to prevent leakage of urine from the basin; and a drain opening in the basin for draining the urine. The urine collection device advantageously prevents leakage and allows for easy access for urine analysis and measurement of urine output. Methods and systems for collecting and quantifying urine are also provided.

Classes IPC  ?

• A61F 5/455 - Réceptacles génitaux pour recueillir l'urine ou d'autres sécrétions des organes féminins
• G01N 1/10 - Dispositifs pour prélever des échantillons à l'état liquide ou fluide

Abrégé

A method for ascertaining pulmonary fibrosis disease progression or treatment response includes obtaining a first set of computed tomography (CT) images of a lung and determining a first Pulmonary Surface Index (PSI) score for the lung by detecting a first actual lung boundary of the lung within the first set of CT images, determining a first approximated lung boundary within the first set of CT images, and determining the PSI score using inputs based on the first actual lung boundary and the first approximated lung boundary. The method also includes obtaining a second set of CT images of the lung and determining a second PSI score for the lung using inputs based on a second actual lung boundary and a second approximated lung boundary. The method also includes assessing pulmonary fibrosis treatment response or disease progression based on the first PSI score and the second PSI score.

Classes IPC  ?

• G06T 7/00 - Analyse d'image

Abrégé

Disclosed herein are methods for removing nonlinear distortions from images of the eye generated optical coherence tomography (OCT) devices. In one aspect, the methods involve applying reference markers of known dimensions to the eye and/or using inherent anatomical features and a second imaging modality to quantify one or more additional reference markers. The methods disclosed herein can be performed with data from any commercial or experimental OCT device without modifying the device. Furthermore, the methods disclosed herein can provide information useful for diagnosis of diseases of the eye such as, for example, glaucoma.

Classes IPC  ?

• A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient

Abrégé

Disclosed are various approaches for estimating uncertainty in deep neural networks. A respective tensor normal distribution can be applied to each of a plurality of convolutional kernels of a convolutional neural network, wherein the respective tensor normal distribution captures a correlation and a variance heteorgeneity of each of the plurality of convolutional kernels. Then, the mean and covariance of each respective tensor normal distribution passing through the non-linear activation function of each nonlinear perceptron can be approximated. Next, a max-pool operation can be performed on a plurality of outputs of the plurality of non-linear perceptrons to generate an output tensor. Then, the output tensor can be vectorized to create an input vector for a fully-connected layer of the convolutional neural network. Subsequently, an output vector can be generated using the fully-connected layer. Then, a mean matrix and a covariance matrix for the output vector can be computed.

Classes IPC  ?

• G06F 15/00 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES Équipement de traitement de données en général
• G06N 3/08 - Méthodes d'apprentissage
• G10L 15/16 - Classement ou recherche de la parole utilisant des réseaux neuronaux artificiels
• H03F 1/26 - Modifications des amplificateurs pour réduire l'influence du bruit provoqué par les éléments amplificateurs

Abrégé

The present technology relates to methods comprising the administration of methotrexate and glucarpidase to treat central nervous system lymphoma in a subject in need thereof. Kits for use in practicing the methods are also provided.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins

Abrégé

Disclosed herein are bilayered substrates useful for treating infection and/or inflammation in a subject such as, for example, the upper respiratory system. In another aspect, the layers of the substrates disclosed herein include biocompatible and biodegradable polymers as well as one or more bioactive agents useful for treating infection and/or inflammation. In a further aspect, the layers of the substrate can contain nanoparticles incorporating the bioactive agents. In any one of the above aspects, the bioactive agents are released at a constant rate over a period of time. In still another aspect, the substrates disclosed herein are useful for reducing the mass of biofilms and reducing or preventing inflammation by inhibiting the production of interleukin-8.

Classes IPC  ?

• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61L 27/54 - Matériaux biologiquement actifs, p.ex. substances thérapeutiques
• A61K 9/70 - Bases pour bande, feuille ou filament
• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments

Abrégé

A method of improving emmetropization or slowing myopia development in an eye is provided that involves adjusting the vision in the eye to achieve one or both of increase the distance between the long-wavelength focal plane and the short wavelength focal plane; and position the short wavelength focal plane closer to the cornea than it would normally be located. Multi-spectral devices (e.g., lenses and spectacles) are provided that are useful to improve emmetropization or preventing or reducing the development of myopia, which are optionally multi-focal as well.

Classes IPC  ?

• G02C 7/04 - Lentilles de contact pour les yeux
• G02C 7/08 - Verres auxiliaires; Dispositions pour faire varier la distance focale
• G02B 1/04 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques faits de substances organiques, p.ex. plastiques

Abrégé

The present disclosure provides methods and compositions for the treatment of NF-1 and NF-1 mediated conditions. The present disclosure further provides for methods of exon skipping and exon retention and compositions for use in such methods. Such methods of exon skipping and exon retention may be used in the methods of treatment discussed herein. The present disclosure further provides new therapeutic compounds, particularly oligonucleotides, including antisense oligonucleotides, for use in the methods described herein.

Classes IPC  ?

• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester 
• A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens

Abrégé

Hemopexin, salubrinal, aurothioglucose, and nitrite find uses in treating pulmonary injury from several causes, alone and in combination. Methods of treatment, methods of prevention, and pharmaceutical compositions are provided with those components.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
• A61K 38/46 - Hydrolases (3)
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
• A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains

Abrégé

Methods for the treatment of lung injury caused by chemical inhalation, smoke inhalation or microbial infection are described. The methods include administering a therapeutically effective amount of nitrite or a nitrite formulation. Nitrite formulations that include a nitrite salt and an anti-caking agent, such as sodium bicarbonate, and the use of such formulations, is also described.

Classes IPC  ?

• A61K 31/375 - Acide ascorbique, c. à d. vitamine C; Ses sels
• A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
• A61K 33/04 - Soufre, sélénium ou tellure; Leurs composés

Abrégé

Provided herein are compositions and methods for increasing fetal hemoglobin in a subject in need thereof. Also provided are compositions and methods for treating a hemoglobin disorder in a subject.

Classes IPC  ?

• A61K 31/17 - Amides, p.ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p.ex. urée, thiourée, carmustine
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides  contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire

Abrégé

The invention relates to methods for diagnosing or assessing the risk of developing chronic lung and bowel disease in pre-term infants by measuring the nitrate reductase activity in oral microbiome samples from the infant. The invention further relates to methods for guiding the care of pre-term infants based on measuring the nitrate reductase activity in oral microbiome samples from the infant.

Classes IPC  ?

• C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une oxydoréductase
• A61K 31/557 - Eicosanoïdes, p.ex. leucotriènes
• A61K 31/198 - Alpha-amino-acides, p.ex. alanine, acide édétique (EDTA)
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Aspects of the present disclosure are related to systems and methods for an analog pulse sequence based encoding and data recovery scheme for high density data communication. One such method comprises generating a plurality of orthogonal pulses; generating a plurality of data sequences based upon different time slot combinations comprising each of the plurality of orthogonal pulses; generating a unified pulse sequence by combining the plurality of data sequences at corresponding time slots; and transmitting the unified pulse sequence.

Classes IPC  ?

• H04L 27/00 - Systèmes à porteuse modulée

Abrégé

A method and computer-based system is provided that assists physicians in detecting early tumor growth and allowing modification of treatment to have a positive impact on medical management, patient morbidity, outcomes and survival times. The method comprises measuring tumor volumes from radiological images to predict growth by a statistical method. The methods allow detection of increases in tumor size earlier than is currently possible and, therefore, advantageous in modifying or optimizing treatment.

Classes IPC  ?

• A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
• A61B 5/066 -
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• G06T 7/00 - Analyse d'image

Abrégé

An AC-electrospinning system and a method are provided for fabricating inorganic fiber tubular structures. The AC-electrospinning system preferably uses an electrode system that comprises an electrical charging component electrode and at least one of an AC field attenuating component and a precursor liquid attenuating component. Use of the AC-eloectrospinning process to fabricate the inorganic fiber tubular structures allows the structures to be made with high porosities that are not achievable using the conventional approach.

Classes IPC  ?

• D01D 5/00 - Formation des filaments, fils ou similaires
• D01F 9/08 - Filaments, ou similaires, faits par l’homme, formés d’autres substances; Leur fabrication; Appareils spécialement adaptés à la fabrication de filaments de carbone de matière inorganique
• D01D 5/24 - Formation des filaments, fils ou similaires à structure creuse; Ensembles de filage à cet effet
• D02G 3/00 - Filés ou fils, p.ex. fils fantaisie; Procédés ou appareils pour leur production non prévus ailleurs
• G05F 1/12 - Régulation de la tension ou de l'intensité là où la variable effectivement régulée par le dispositif de réglage final est du type alternatif
• B29C 47/00 - Moulage par extrusion, c. à d. en exprimant la matière à mouler dans une matrice ou une filière qui lui donne la forme désirée; Appareils à cet effet (moulage par extrusion-soufflage B29C 49/04)
• B29C 48/14 - Moulage par extrusion, c. à d. en exprimant la matière à mouler dans une matrice ou une filière qui lui donne la forme désirée; Appareils à cet effet caractérisés par les conditions particulières d’extrusion, p.ex. dans une atmosphère modifiée ou par l’utilisation de vibrations

Abrégé

A method is provided for increasing the sensitivity of the complement-dependent cellular cytoxicity analysis that establishes whether a potential transplant recipient patient expresses donor organ-reactive antibodies that would reduce or prevent acceptance of the donor organ by a recipient. At least one gene encoding a complement inhibitor is inactivated in cells derived from a candidate transplant organ. Such modified cells, because they no longer produce at least one complement inhibitor, when placed in a serum sample from a potential transplant recipient, do not reduce the effective activity of serum complement. A lower level of recipient patient serum antibodies becomes effective in inducing detectable lysis of the donor cells.

Classes IPC  ?

• G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A number of MS- and natural-saponin-based vaccine adjuvant candidates have been prepared. The MS derivatives were prepared by incorporating a terminal-functionalized side chain into the C3 glucuronic acid unit of the natural saponins MS I and II through amide formation reaction; and the QS analogs were prepared via multi-step organic synthesis. These unnatural saponins showed significantly different immunostimulant activity profiles, suggesting that the structure of side chain, triterpenoid core, and oligosaccharide domain together orchestrate each saponin's characteristic potentiation of immune responses.

Classes IPC  ?

• A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
• A61K 47/28 - Stéroïdes, p.ex. cholestérol, acides biliaires ou acide glycyrrhétinique
• A61K 9/107 - Emulsions

Abrégé

Disclosed are various embodiments for sensing and integrating data of environmental conditions in animal research. A collection device having a bracket is removably mounted to a cage. The collection device includes a sensor array that captures audio content or environmental measurements. A micro-environment monitor of the collection device can process the audio content to determine that audible or ultrasonic vocalizations of an animal are present. The micro-environment monitor sends data based at least in part on the audio content or environmental measurements to a computing environment.

Classes IPC  ?

• A01K 1/03 - Logements pour animaux domestiques ou de laboratoire
• A01K 29/00 - Autres appareils pour l'élevage
• A61D 17/00 - Dispositifs pour signaler des troubles pendant que l'animal est en travail
• A01K 67/02 - Obtention de vertébrés
• H04N 7/18 - Systèmes de télévision en circuit fermé [CCTV], c. à d. systèmes dans lesquels le signal vidéo n'est pas diffusé

Abrégé

Methods for the treatment of a polyomavirus infection, for decreasing the viral titer of a PyV in a subject having a PyV infection, for treating a adverse effect of a treatment that suppresses the immune system, for inhibiting the DNA damage response pathway, and related methods are provided. Compounds, kits, and composition usefule in the described methods are also provided. Suitable compounds useful in the methods disclosed include inhibitors of ataxia telangiectasia mutated and ATM-Rad 3 related proteins.

Classes IPC  ?

• A61K 35/76 - Virus; Particules sous-virales; Bactériophages
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

This invention includes methods for assessing and treating risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, for example rheumatoid arthritis (RA). Provided are methods for assessing risk, for recommending therapy, for prognosis and monitoring, and for treatment, which are advantageously accurate for CVD in RA. The methods include measuring quantitative data for biomarkers, calculating a CVD risk score for a subject using training data, and validating the CVD risk score with a set of validation clinical data.

Classes IPC  ?

• G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G06N 3/02 - Réseaux neuronaux

Abrégé

The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of adenovirus infection in humans and other mammals. Disclosed are methods of treating or preventing adenovirus infections in mammals by administration of an effective amount of filociclovir (FCV).

Classes IPC  ?

• A61P 31/12 - Antiviraux
• A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides 
• A61K 31/195 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino

Abrégé

An electrode system for use in an AC-electrospinning process comprises an electrical charging component electrode and at least one of an AC field attenuating component and a precursor liquid attenuating component. The electrical charging component electrode is electrically coupled to an AC source that places a predetermined AC voltage on the electrical charging component electrode. In cases in which the electrode system includes the AC field attenuating component, it attenuates the AC field generated by the electrical charging component electrode to better shape and control the direction of the fibrous flow. In cases in which the electrode system includes the precursor liquid attenuating component, it serves to increase fiber generation, even if the top surface of the liquid precursor is not ideally shaped or is below a rim or lip of the reservoir that contains the liquid on the electrical charging component electrode.

Classes IPC  ?

• D01D 5/08 - Méthodes de filage à partir de masses en fusion
• D01D 5/084 - Chauffage des filaments, fils ou similaires, à la sortie des filières
• D01D 5/38 - Formation de filaments, fils, ou similaires pendant la polymérisation
• D01D 5/10 - Méthodes de filage à partir de masses en fusion utilisant des matières organiques
• D01D 5/02 - Démarrage de la fabrication
• D01D 5/04 - Méthodes de filage à sec
• D01D 5/06 - Méthodes de filage au mouillé
• D01D 5/11 - Filage éclair
• D01D 5/24 - Formation des filaments, fils ou similaires à structure creuse; Ensembles de filage à cet effet
• D01D 5/247 - Structure creuse discontinue ou structure microporeuse
• D01D 5/28 - Formation des filaments, fils ou similaires avec mélange des différentes solutions ou masses de filage au cours du filage; Ensembles de filage à cet effet

Abrégé

Provided herein are methods and compositions for treating and preventing inflammatory bowel disease.

Classes IPC  ?

• A61K 31/155 - Amidines (), p.ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
• A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
• A61K 38/20 - Interleukines
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
• C07K 14/33 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Clostridium (G)

Abrégé

This invention relates to fusion proteins, nucleic acid molecules, DNA constructs, and pharmaceutical compositions comprising the same, and methods of their use in IL10 antagonism.

Classes IPC  ?

• A61K 38/20 - Interleukines
• C07K 14/54 - Interleukines (IL)

Abrégé

A culture chamber system is described. In one example, it includes a culture chamber, where the culture chamber includes a well, a flexible membrane enclosing a side of the well, and a pair of posts extending within the well and each adhered at one end to the flexible membrane. Cells, such as cardiac cells, are grown into a tissue between the posts. The culture chamber system further includes a flow loop to supply media to the well in a first phase of a cycle, and the flexible membrane distends due to a weight of the media in the well in the first phase of the cycle. The culture chamber system further includes a support base to buttress a distention of the membrane due to the weight of the media in the well, and a pump to oppose the distention of the membrane during a second phase of the cycle.

Classes IPC  ?

• B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en général; Appareils appropriés
• B01L 1/02 - Chambres pressurisées; Leurs sas
• F16K 7/07 - Dispositifs d'obturation à diaphragme, p.ex. dont un élément est déformé, sans être déplacé entièrement, pour fermer l'ouverture à diaphragme tubulaire dont l'étranglement est assuré par une force extérieure radiale par pression d'un fluide
• F16K 7/12 - Dispositifs d'obturation à diaphragme, p.ex. dont un élément est déformé, sans être déplacé entièrement, pour fermer l'ouverture à diaphragme plat, en forme d'assiette ou en forme de bol
• F16K 31/126 - Moyens de fonctionnement; Dispositifs de retour à la position de repos actionnés par un fluide le fluide agissant sur un diaphragme, un soufflet ou un organe similaire
• F16K 39/00 - Dispositifs pour relâcher la pression sur les faces d'un joint d'étanchéité
• F16L 55/02 - Absorbeurs d'énergie; Absorbeurs de bruit

Abrégé

Methods and systems for providing continuous renal replacement therapy (CRRT) to a patient are provided. The system includes a hemofiltration unit that provides continuous venovenous hemofiltration (CVVH), a replacement fluid flow regulator configured to regulate the flow of a replacement fluid, an anticoagulant flow regulator configured to pump an anticoagulant, and a blood warmer. The system provides enhanced communication between the hemofiltration unit and the replacement fluid flow regulator. The system may be used to treat patients having renal insufficiency, such as acute kidney injury.

Classes IPC  ?

• A61M 1/14 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang
• A61M 1/34 - Filtration du sang à travers une membrane pour en éliminer une matière, c. à d. hémofiltration, diafiltration
• A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p.ex. adaptation de la température, irradiation
• A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
• A61M 39/10 - Raccords ou accouplements pour tubes

Abrégé

Methods and systems for providing continuous renal replacement therapy (CRRT) to a patient are provided. The system includes a hemofiltration unit that provides continuous venovenous hemofiltration (CVVH), a replacement fluid flow regulator configured to regulate the flow of a replacement fluid, an anticoagulant flow regulator configured to pump an anticoagulant, and a blood warmer. The system provides enhanced access to the extracorporeal circuit for blood analysion, infusion of products and/or anticoagulation control. The system may be used to treat patients having renal insufficiency.

Classes IPC  ?

• A61M 1/16 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang avec membranes
• A61M 1/14 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang
• A61M 1/18 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang avec membranes en forme de fibres creuses
• A61M 1/34 - Filtration du sang à travers une membrane pour en éliminer une matière, c. à d. hémofiltration, diafiltration

Abrégé

The invention provides combination therapies for treating cancer comprising compositions and methods for γδ T cell immunotherapy in combination DDR inhibitors, including but not limited to PARP inhibitors. Preferably, the combination of γδ T cell immunotherapy and PARP inhibitors for the treatment of cancer further includes combinations with other immunotherapies such as immune checkpoint (ICP) blockade therapy and/or DNA damaging agents such as cytotoxic chemotherapeutic agents. Preferably, when the combination of γδ T cell immunotherapy and DDR inhibitor therapy further include chemotherapeutic agents, the γδ T cells are genetically modified to impart resistance to that chemotherapeutic agent.

Classes IPC  ?

• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
• C12N 15/09 - Technologie d'ADN recombinant
• A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux

Abrégé

A majority of neuroendocrine (NE) cancers overexpress somatostatin receptors (SSTRs). Disclosed herein are anti-SSTR2 monoclonal antibodies, and antibody-drug conjugates (ADCs) for use as NE cancer targeting therapeutics. Also disclosed is an isolated nucleic acid encoding the disclosed antibodies, as well as nucleic acid vectors containing this isolated nucleic acid operably linked to an expression control sequence. Also disclosed are cells transfected with these vectors and the use of these cells to produce the disclosed recombinant antibodies. Also disclosed is a method of treating a neuroendocrine (NE) cancer in a subject, comprising administering to the subject an effective amount of the disclosed antibody conjugated to an anti-cancer agent.

Classes IPC  ?

• C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 38/00 - Préparations médicinales contenant des peptides
• C12P 21/08 - Anticorps monoclonaux

Abrégé

Heterocyclic compounds with a novel pyrazole thioamide-based NNSN structural motif, having highly effective zinc- or copper-activated toxicity against microbial infections at micromolar or nanomolar minimum inhibitory concentrations (MIC), and methods of making and using the same.

Classes IPC  ?

• A61K 31/17 - Amides, p.ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p.ex. urée, thiourée, carmustine
• A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 31/04 - Agents antibactériens

Abrégé

The present disclosure provides a screening assay that detects the binding between FGF23 and FGFR4 in a very sensitive and quantitative manner that can be used to identify modulator compounds (i.e., inhibitor compounds and stimulator compounds) of FGF23-FGFR4 binding with high specificity. The disclosed methods can be used in a high-throughput format to screen large numbers of candidate compounds, and is cost-effective. The present disclosure also provides for modulator compounds (i.e., inhibitor compounds and stimulator compounds) that are identified by the assays disclosed as well as pharmaceutical formulations comprising such identified modulator compounds. Further, the present disclosure provides for methods of using the identified modulator compounds in methods of treating a disease or condition in a subject.

Classes IPC  ?

• G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
• C12Q 1/6811 - Méthodes de sélection pour la production ou l’élaboration d’oligonucléotides spécifiques cibles ou de molécules de liaison

Abrégé

The present disclosure provides a screening assay that detects soluble klotho polypeptide in a sample. The described assay is sensitive and quantitative, can be used in a high-throughput format, and is cost-effective. The present disclosure also provides for specific uses of such an assay. Further, the present disclosure provides for kits comprising one or more components required for practicing the assay. Furthermore, the present disclosure provides a specific procedure for the synthesis and purification of bioactive recombinant sKL protein.

Classes IPC  ?

• C07K 14/71 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des régulateurs de croissance
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/40 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Abrégé

The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• A61K 35/34 - Muscles; Cellules musculaires lisses; Cœur; Cellules souches cardiaques; Myoblastes; Myocytes; Cardiomyocytes
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspension; Leur conservation; Milieux de culture à cet effet
• C12N 5/074 - Cellules souches adultes

Abrégé

The present invention provides an attenuated Old World alphavirus particle and methods of making same and using same as a vaccine and in gene therapy and immunotherapy methods.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Provided herein is a method for identifying compounds that inhibit cell growth or have cytotoxic activity against cancer cells, such as hematological cancer cells or ovarian cancer cells, in a subject. Further provided is a method for identifying one or more compounds that sensitize refractory cancer cells from a subject. Also provided are compositions and methods for treating cancer, including refractory cancer, such as refractory acute myeloid leukemia (AML) or ovarian cancer.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12N 5/078 - Cellules du sang ou du système immunitaire
• C12N 5/09 - Cellules tumorales
• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

Disclosed herein are methods of treating or preventing a disease caused by nonsense mutations, or ameliorating one or more symptoms associated therewith, that involve administering to a patient in need thereof a therapeutically or prophylactically effective amount of triamterene, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug, or polymorph thereof.

Classes IPC  ?

• A61K 31/132 - Amines, p.ex. amantadine ayant plusieurs groupes amino, p.ex. spermidine, putrescine
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• C07D 487/02 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient deux hétérocycles
• C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

Various embodiments for a coiled containment guardrail system and terminal are described. A guardrail system can include a terminal head configured for placement at a distal end of a guardrail beam, where the terminal head includes a canister having a hollow interior and an impact surface. A chute can be coupled to the terminal head, where the chute is configured to guide a guardrail beam into the terminal head in response to an impact being experienced at the impact surface. The terminal head may further include a flattening device coupled to the chute configured to flatten the guardrail beam in response to the impact being experienced at the terminal head. The canister can be configured to coil and store the guardrail beam as flattened by the flattening device in the hollow interior of the canister.

Classes IPC  ?

• E01F 15/14 - Dispositions de sécurité pour ralentir, maintenir sur la route ou arrêter les véhicules à la dérive, p.ex. bornes de protection ou pieux garde-fous; Dispositions pour réduire les dommages occasionnés aux structures du bord de la route par l'impact de véhicules spécialement adaptées pour une protection localisée, p.ex. pour piles de ponts, pour îlots de circulation

Abrégé

Disclosed herein is an optogenetics-based gene therapy that involves channelrhodopsin fusion proteins having an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS) that can effectively target the fusion protein to an inner mitochondria membrane, and a channelrhodopsin ion channel domain that can change the mitochondrial membrane potential (ΔΨm) when light is present. The disclosed optogenetics-based gene therapy system can in some embodiments further involve luciferase fusion proteins to stimulate the channelrhodopsin without reliance on external light that has an outer mitochondrial membrane-mitochondrial localization signal (OMM-MLS) that can effectively target the luciferase fusion protein to an outer mitochondrial membrane, and a luciferase protein that can produce a bioluminescence in the presence of a luciferase substrate.

Classes IPC  ?

• C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

StreptococcusStreptococcus biofilm formation, as well as for preventing, inhibiting and/or treating the formation of dental caries, and methods of identifying compounds that prevent, inhibit and/or treat the formation of dental caries are provided.

Classes IPC  ?

• C07C 49/835 - Cétones comportant un groupe cétone lié à un cycle aromatique à six chaînons contenant des groupes hydroxyle avec insaturation autre que celle d'un cycle aromatique
• C07D 215/48 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• A61K 31/121 - Cétones acycliques
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/47 - Quinoléines; Isoquinoléines
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61P 31/04 - Agents antibactériens
• A61P 1/02 - Préparations stomatologiques, p.ex. médicaments pour le traitement des caries, des aphtes, des périodontites
• G01N 33/573 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour enzymes ou isoenzymes
• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

Quillaja saponaria Quillaja saponaria (QS) Molina tree bark that are chemically modified to distinguish them from naturally occurring parent saponins. The modified saponins have increased adjunctive activity compared to the unmodified parent saponins. Defined structures allow for comparisons of the modifying groups with respect to their respective adjunct activity and permit characterized vaccine formulations that have one or more defined saponins.

Classes IPC  ?

• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• C07H 15/20 - Carbocycles
• C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p.ex. cholane, cholestane, coprostane

Abrégé

Relationships between morphological changes to an eye due to intraocular pressure changes and blood perfusion changes in the retina are determined by colocalizing retinal perfusion data and optic nerve head (ONH) mechanical deformation data. Perfusion changes from intraocular pressure (IOP) changes are determined by colocalizing retinal perfusion data with ONH mechanical deformation data. Optical coherence tomography-angiography (OCT-A) can be used to generate both retinal perfusion data and mechanical deformation data for an imaged volume. A three-dimensional model (e.g., connectivity map or connectivity model) of the vasculature can be generated from the OCT-A imaging data and used to predict changes in blood perfusion in various areas of the retina due to IOP-induced mechanical deformations.

Classes IPC  ?

• A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
• A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
• A61B 3/16 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la pression intraoculaire, p.ex. tonomètres
• A61B 6/03 - Tomographes assistés par ordinateur
• A61B 8/10 - Examen de l'œil
• A61B 8/13 - Tomographie

Abrégé

In one aspect, the present invention provides recombinant polynucleotides. In some embodiments, the recombinant polynucleotides comprise a cytomegalovirus (CMV) genome, or a portion thereof, and a nucleic acid sequence encoding an antigen, wherein the CMV genome or portion thereof comprises a mutation within a interleukin-10-like gene sequence. Methods for preventing and treating diseases such as infectious diseases and cancer are also provided herein.

Classes IPC  ?

• A61K 39/245 - Herpetoviridae, p.ex. virus de l'Herpès simplex
• C07K 14/045 - Cytomégalovirus
• C12N 15/38 - Herpétoviridae, p.ex. virus de l'herpès simplex, herpesvirus varicellae, virus Epstein-Barr, cytomégalovirus, virus de la pseudorage

Abrégé

The present disclosure relates to a composite frost plate adapted to engage with a water meter and formed of a discontinuous fiber reinforced matrix composite. The composite frost plate can include a first surface, a second surface opposing that of the first surface, a domed center portion sized and positioned to engage with an opening on a water vessel, and an outer portion configured for attachment to the water vessel. The outer portion can include a plurality of slotted bolting lugs, the outer portion formed to comprise at least one stiffener disposed at a periphery of the domed center portion. Where the second surface can be sized and positioned to be substantially flat at the outer portion to face the water vessel when the composite frost plate is coupled to the water vessel.

Classes IPC  ?

• G01F 1/05 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu en utilisant des effets mécaniques
• G01F 15/10 - Prévention des avaries par le gel ou par suite d'un excès ou d'une insuffisance de pression
• E03B 7/00 - Canalisations principales ou réseaux de distribution
• F25D 21/00 - Dégivrage; Prévention du givrage; Evacuation du condensat ou de l'eau de dégivrage

Abrégé

Provided herein are methods for treating and preventing PD-1-mediated resistant cancers.

Classes IPC  ?

• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61P 35/00 - Agents anticancéreux

Abrégé

In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels.

Classes IPC  ?

• A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
• A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61P 3/06 - Antihyperlipémiants
• A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques

Abrégé

The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• A61K 31/4245 - Oxadiazoles
• C07D 271/06 - Oxadiazoles-1, 2, 4; Oxadiazoles-1, 2, 4 hydrogénés
• C07D 285/08 - Thiadiazoles-1, 2, 4; Thiadiazoles-1, 2, 4 hydrogénés

Abrégé

The present disclosure is concerned with dipeptide analogs that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, methods for immunotherapy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Classes IPC  ?

• A61K 38/05 - Dipeptides
• C07K 5/06 - Dipeptides
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to identification of focal areas of abnormal interactions in a brain of an anesthetized subject. During the maintenance period of anesthesia and/or the post-emergence period of anesthesia, neurophysiological time series signals from two or more areas of the brain of the subject can be recorded. A system that includes a processor can receive these signals, estimate a percentage of time (POT) each of the two or more areas of the brain of the subject exhibits a maximum total effective inflow (TEI) of information, and localize one or more focal areas of abnormal brain interactions based on the POT of each of the at least two areas exhibiting maximum TEI.

Classes IPC  ?

• A61B 5/04 - Mesure de signaux bioélectriques du corps ou de parties de celui-ci
• A61B 5/0476 - Electro-encéphalographie

Abrégé

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting epression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

A multimodal interferometric tear film measurement system can include an optical coherence tomography (OCT) system and a thickness dependent fringe (TDF) system. The multimodal interferometric tear film measurement system (multimodal interferometry system) can include a hot mirror dual focusing system that allows the OCT system's light signals and the TDF system's light signals to be individually focused while both are simultaneously directed towards the eye. The multimodal interferometry system can provide OCT and TDF measurements simultaneously. The OCT system can provide measurements of the thickness of the entire tear film, while the TDF system can provide measurements of the thickness of the lipid layer of the tear film. The multimodal interferometry system can provide in vivo measurements of both lipid layer and overall tear film.

Classes IPC  ?

• A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient

Abrégé

The blood capillary refill simulator provides a dynamic method of simulating capillary refill action in a patient, especially adolescents. The simulator as a teaching device is capable of simulating the refill action multiple times across multiple simulations. The blood capillary refill simulator uses a pressure sensor(s) in the fingertip of a simulation finger or arm that, when pressed, activates a light source housed within the fingertip. When the pressure sensor(s) is released, the light will fade out completely. A program controls the length of time it takes for the light to completely fade out. A user can select a time interval in seconds for the light to fade out which can be modified during the simulation by the operator. If the pressure sensor(s) is pressed while the fade out is occurring, the light source will restart at full brightness and fade out for the specified time interval.

Classes IPC  ?

• G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p.ex. dispositif en vraie grandeur pour la démonstration pour la médecine
• G09B 23/30 - Modèles anatomiques
• G09B 23/34 - Modèles anatomiques avec des parties amovibles

Abrégé

The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

A transport chair is provided that includes a base frame, a seat assembly pivotally mounted to the base, and a footrest assembly pivotally mounted to the base frame, the footrest assembly being associated with the seat assembly so as to pivot in unison with the seat assembly until the seat assembly is pivoted forward to an extent at which the footrest assembly contacts the floor or ground, at which point the footrest assembly does not pivot further upon further forward pivoting of the seat assembly. Further embodiments of the transport chair allow the seat assembly to recline, alone or in unison with a leg rest assembly, while the footrest remains in position

Classes IPC  ?

• A61F 5/10 - Dispositifs pour rectifier les difformités des doigts

Abrégé

Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.

Classes IPC  ?

• C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus

Abrégé

The present disclosure relates to devices and methods for the removal of a section of tissue from a subject, such as the removal of a section of colon from within the lumen of the large intestine of a subject. The device generally comprises a cylindrical housing comprising an inlet, an outer cavity connected to the inlet, an inversion device, a stapling controller and a cutting controller, wherein the stapling controller is configured to operate a stapling head located within the housing and wherein the cutting controller is configured to operate a cutting head located within the housing. The housing may surround a portion of an endoscope, such as a colonoscope, such that the colonoscope passes through an inner cavity of the device. Methods of using the device generally comprise the steps of: inserting the device into a subject's rectum; advancing the device through the colon to the area of interest; inverting of the area of interest using the inversion device; stapling non-adjacent areas of the colon together; resecting the area of interest; and retracting the device.

Classes IPC  ?

• A61B 17/068 - Agrafeuses chirurgicales
• A61B 17/3205 - Instruments pour l'excision

Abrégé

The present invention relates to imaging systems, and in particular to common-path phase-sensitive optical coherence tomography for enhanced phase stability and detection sensitivity. Particularly, aspects are directed to an optical imaging system including a source for generating a coherent beam of electromagnetic radiation, a reference plane defined by an optical surface for back-reflecting a reference arm of the coherent beam of electromagnetic radiation with a first optical signal, and a sample for back-reflecting a sample arm of the coherent beam of electromagnetic radiation with a second optical signal. The optical surface is located near or adjacent to the sample, and after back-reflecting, the reference arm and the sample arm are configured to interfere and create an interference signal based upon a phase difference between the first optical signal and the second optical signal and a time delay of the reference arm from the sample arm.

Classes IPC  ?

• G01B 9/02 - Interféromètres
• A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
• A61B 8/08 - Détection de mouvements ou de changements organiques, p.ex. tumeurs, kystes, gonflements
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/06 - Dispositifs autres que ceux à radiation, pour détecter ou localiser les corps étrangers

Abrégé

Various embodiments for sustained drug delivery using a needle array are disclosed. A medical instrument and a method associated therewith are described for delivering drugs into tonsillar and other tissue as a way of treating tonsillar hypertrophy or inflammation, as an alternative to tonsillectomy and adenoidectomy (T&A) procedures. In some embodiments, a tonsil-accessible medical instrument is described as including a needle head having needles, or microneedles, disposed therein and capable of introducing a compound, such as a steroid, into tissue. The medical instruments enables for the delivery of various compounds, such as pharmaceuticals, for controlled and sustained release.

Classes IPC  ?

• A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p.ex. de remèdes, dans les cavités du corps
• A61B 17/24 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets pour la cavité buccale, le larynx, les conduits des bronches ou le nez; Grattoirs pour la langue

Abrégé

Provided herein are mass spectrometric standards for distinguishing hemoglobin beta (HBB) and hemoglobin beta sickle (HBS) and methods of using these standards to determine the amount of HBB relative to HBS in a sample.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
• G01N 30/02 - Chromatographie sur colonne
• G01N 33/96 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir un étalon de contrôle du sang ou du sérum